Table 3.
Univariable comparisons between demographics, comorbidities, treatments, and serum laboratory values for cancer patients treated with chemotherapy stratified by probability of fibrosis as determined by APRI
| Variable | Low probability (n = 75) | Other (n = 42) | Univariable p | Multivariable p | OR (95 % CI) |
|---|---|---|---|---|---|
| Demographics and comorbidities | |||||
| Age (years), mean ± SE | 58.5 ± 1.4 | 60.4 ± 1.8 | 0.41 | – | – |
| Female, n (%) | 40 (53.3) | 24 (57.1) | 0.69 | – | – |
| Ethnicity, n (%) | 0.28 | – | – | ||
| White | 59 (78.7) | 28 (66.7) | – | – | |
| Black | 10 (13.3) | 7 (16.7) | – | – | |
| Other | 6 (8.0) | 7 (16.7) | – | – | |
| Body mass index (kg/m2), mean ± SE | 29.9 ± 0.8 | 30.7 ± 1.6 | 0.67 | – | – |
| Hypertension, n (%) | 51 (68.0) | 27 (64.3) | 0.68 | – | – |
| Diabetes mellitus, n (%) | 21 (28.0) | 12 (28.6) | 0.95 | – | – |
| Dyslipidemia, n (%) | 35 (46.7) | 16 (38.1) | 0.37 | – | – |
| Metabolic syndrome, n (%) | 24 (32.0) | 11 (26.2) | – | – | |
| Cancer type | 0.16 | – | – | ||
| Gastrointestinal, n (%) | 39 (52.0) | 28 (66.7) | – | – | |
| Soft tissue, n (%) | 17 (22.7) | 8 (19.1) | – | – | |
| Genitourinary, n (%) | 8 (10.7) | 5 (11.9) | – | – | |
| Other, n (%) | 11 (14.7) | 1 (2.4) | – | – | |
| Serum laboratory values | |||||
| Alanine aminotransferase (U/L), mean ± SE | 26.8 ± 1.5 | 57.4 ± 6.9 | <0.01 | <0.01 | 0.449 [0.291–0.638] |
| Aspartate aminotransferase (U/L), mean ± SE | 24.1 ± 1.0 | 55.7 ± 4.9 | <0.01 | – | – |
| Total bilirubin (mg/dL), mean ± SE | 0.61 ± 0.03 | 1.02 ± 0.21 | 0.08 | 0.03 | 0.419 [0.185–0.877]† |
| Alkaline phosphatase (U/L), mean ± SE | 98.4 ± 8.3 | 127.7 ± 15.6 | 0.10 | 0.45 | 1.066 [0.890–1.241]‡ |
| Albumin (mg/dL) | 3.69 ± 0.05 | 3.56 ± 0.08 | 0.20 | – | – |
| Creatinine (mg/dL), mean ± SE | 0.88 ± 0.03 | 0.88 ± 0.05 | 0.87 | – | – |
| Hemoglobin (g/dL), mean ± SE | 12.5 ± 0.2 | 11.6 ± 0.3 | 0.04 | 0.05 | 1.153 [0.996–1.345]¥ |
| Hematocrit (%), mean ± SE | 37.7 ± 0.6 | 34.7 ± 0.9 | <0.01 | – | – |
| Platelets (thousand/μL), mean ± SE | 246.0 ± 9.4 | 173.5 ± 11.6 | <0.01 | – | – |
| Diagnostic radiologic imaging | 0.91 | – | – | ||
| Computed tomography, n (%) | 70 (93.3) | 39 (92.9) | – | – | |
| Ultrasound, n (%) | 4 (5.3) | 2 (4.8) | – | – | |
| Magnetic resonance imaging, n (%) | 1 (1.3) | 1 (2.3) | – | – | |
| Duration of chemotherapy (cycles) | 7.8 ± 0.5 | 7.5 ± 0.7 | 0.67 | – | – |
| Irinotecan or 5-fluorouracil | 28 (37.3) | 28 (66.7) | <0.01 | 0.02 | 0.277 [0.091–0.779] |
| Interval from last chemotherapy (months) | 24.3 ± 2.9 | 21.4 ± 4.6 | 0.547 | – | – |
| Anti-biologic therapy | 12 (16.0) | 2 (4.8) | 0.08 | 0.46 | 1.901 [0.395–14.241] |
Multivariable analysis for the end point of low probability of fibrosis is included
SE standard error, APRI AST-to-platelet ratio index
Units:
*
10 U/L;
†
0.5 mg/dL;
‡
20 U/L;
¥
0.5 g/dL